期刊
DIABETES TECHNOLOGY & THERAPEUTICS
卷 13, 期 6, 页码 601-606出版社
MARY ANN LIEBERT, INC
DOI: 10.1089/dia.2010.0225
关键词
-
资金
- Medtronic
- Novo Nordisk
- Amylin
- Becton Dickinson
- Eli Lilly
- Hoffmann-La Roche
- GlycoMark
- Wyeth
- Daiichi Sankyo
- Bristol-Myers Squibb
- Bayhill Therapeutics
- LipoScience
- MannKind
- Valeritas
- MicroIslet
- GlaxoSmithKline
- Abbott
- Exsulin
- GI Dynamics
- Lilly
- Novartis
- Tolerex
- Osiris
- Halozyme
- Pfizer
- Interkrin
- Merck
- sanofi-aventis
- DexCom
- Johnson Johnson
- Fujisawa
- Abbott Diabetes Care
- Bayer
- Calibra
- Intarcia
- ResMed
- Roche
- Takeda
- Biodel
- Hygieia
- Intuity
- LifeScan
- UnitedHealth Group
- VeroScience
- Johnson and Johnson
- CPEX Pharmaceuticals
Background: Baseline characteristics from the adult cohort of a randomized controlled trial comparing sensor-augmented pump (SAP) and multiple daily injection (MDI) therapy were analyzed for significant relationships with -0.5% A1C change at 1 year of therapy without incidence of severe hypoglycemia (defined as A1C benefit). Methods: Baseline characteristics were compared with A1C benefit. Statistically significant predictors were analyzed further to determine appropriate cutpoints of relative A1C benefit. Results: Baseline A1C >= 9.1%, age at randomization >= 36 years, and age at diabetes diagnosis of >= 17 years were associated with a greater SAP benefit relative to MDI than other cutpoints. Conclusions: People with type 1 diabetes who had a high A1C and who were older at diagnosis and older at randomization experienced the most benefit from SAP therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据